Analysts Set Qiagen (NYSE:QGEN) Price Target at $51.15

Qiagen (NYSE:QGEN) has received an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $51.88.

A number of research firms have weighed in on QGEN. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and issued a $54.00 price target (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a report on Thursday, October 17th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. CWM LLC raised its position in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Qiagen by 21.0% in the 2nd quarter. Blue Trust Inc. now owns 7,891 shares of the company’s stock valued at $339,000 after buying an additional 1,369 shares during the period. Raymond James & Associates grew its position in shares of Qiagen by 12.7% during the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after buying an additional 61,008 shares during the last quarter. Mayfair Advisory Group LLC bought a new stake in shares of Qiagen during the 2nd quarter valued at about $268,000. Finally, Fifth Third Bancorp raised its stake in Qiagen by 9.4% during the second quarter. Fifth Third Bancorp now owns 76,592 shares of the company’s stock worth $3,147,000 after acquiring an additional 6,573 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of QGEN stock opened at $44.67 on Friday. The firm has a fifty day simple moving average of $43.32 and a 200-day simple moving average of $43.77. The company has a market capitalization of $10.19 billion, a PE ratio of 114.54, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.